{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-331522","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2026-08-04T11:09:08+00:00","discovered_at":"2026-08-04T11:10:03.447898+00:00","generated_at":"2026-08-04T11:10:10.114472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Beam Therapeutics Q2 net loss $122.7M; first patient dosed in BEAM-302 pivotal trial","bullets":["Net loss of $122.7M ($1.18 per share) vs $102.1M loss in Q2 2025; R&D expenses $95.1M.","First patient dosed in global pivotal cohort of BEAM-302 for AATD; updated data at ERS Congress Sept 2026.","Dosing complete for all patients in BEACON trial of risto-cel for SCD; BLA submission expected as early as year-end 2026.","FDA cleared IND for BEAM-304 in PKU; clinical start-up activities underway.","Cash $1.2B as of June 30, 2026; with $200M from Sixth Street, runway into mid-2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-331522","json":"https://secwatch.observer/filing/0001193125-26-331522.json","markdown":"https://secwatch.observer/filing/0001193125-26-331522.md","text":"https://secwatch.observer/filing/0001193125-26-331522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/0001193125-26-331522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:10:10.114472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}